177 related articles for article (PubMed ID: 25057168)
1. Evaluating surrogacy metrics and investigating approval decisions of progression-free survival (PFS) in metastatic renal cell cancer: a systematic review.
Johnson KR; Liauw W; Lassere MN
Ann Oncol; 2015 Mar; 26(3):485-96. PubMed ID: 25057168
[TBL] [Abstract][Full Text] [Related]
2. Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy.
Kim SH; Park WS; Kim SH; Joung JY; Seo HK; Lee KH; Chung J
Cancer Res Treat; 2016 Jul; 48(3):1092-101. PubMed ID: 26875203
[TBL] [Abstract][Full Text] [Related]
3. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Grünwald V; Lin X; Kalanovic D; Simantov R
Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
[TBL] [Abstract][Full Text] [Related]
4. Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL).
Shi Q; Schmitz N; Ou FS; Dixon JG; Cunningham D; Pfreundschuh M; Seymour JF; Jaeger U; Habermann TM; Haioun C; Tilly H; Ghesquieres H; Merli F; Ziepert M; Herbrecht R; Flament J; Fu T; Coiffier B; Flowers CR
J Clin Oncol; 2018 Sep; 36(25):2593-2602. PubMed ID: 29975624
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials.
Mushti SL; Mulkey F; Sridhara R
Clin Cancer Res; 2018 May; 24(10):2268-2275. PubMed ID: 29326281
[No Abstract] [Full Text] [Related]
6. Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma.
Halabi S; Rini B; Escudier B; Stadler WM; Small EJ
Cancer; 2014 Jan; 120(1):52-60. PubMed ID: 24347384
[TBL] [Abstract][Full Text] [Related]
7. Real life patterns of care and progression free survival in metastatic renal cell carcinoma patients: retrospective analysis of cross-sectional data.
Maroun R; Mitrofan L; Benjamin L; Nachbaur G; Maunoury F; Le Jeunne P; Durand-Zaleski I
BMC Cancer; 2018 Feb; 18(1):214. PubMed ID: 29466966
[TBL] [Abstract][Full Text] [Related]
8. Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer.
Hamada T; Nakai Y; Isayama H; Yasunaga H; Matsui H; Takahara N; Mizuno S; Kogure H; Matsubara S; Yamamoto N; Tada M; Koike K
Eur J Cancer; 2016 Sep; 65():11-20. PubMed ID: 27451020
[TBL] [Abstract][Full Text] [Related]
9. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
Eichelberg C; Vervenne WL; De Santis M; Fischer von Weikersthal L; Goebell PJ; Lerchenmüller C; Zimmermann U; Bos MM; Freier W; Schirrmacher-Memmel S; Staehler M; Pahernik S; Los M; Schenck M; Flörcken A; van Arkel C; Hauswald K; Indorf M; Gottstein D; Michel MS
Eur Urol; 2015 Nov; 68(5):837-47. PubMed ID: 25952317
[TBL] [Abstract][Full Text] [Related]
10. Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma.
Négrier S; Bushmakin AG; Cappelleri JC; Korytowsky B; Sandin R; Charbonneau C; Michaelson MD; Figlin RA; Motzer RJ
Eur J Cancer; 2014 Jul; 50(10):1766-1771. PubMed ID: 24768571
[TBL] [Abstract][Full Text] [Related]
11. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
[TBL] [Abstract][Full Text] [Related]
12. Surrogate endpoints for overall survival in combined chemotherapy and radiotherapy trials in nasopharyngeal carcinoma: Meta-analysis of randomised controlled trials.
Chen YP; Sun Y; Chen L; Mao YP; Tang LL; Li WF; Liu X; Zhang WN; Zhou GQ; Guo R; Lin AH; Ma J
Radiother Oncol; 2015 Aug; 116(2):157-66. PubMed ID: 26243677
[TBL] [Abstract][Full Text] [Related]
13. Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma.
Delea TE; Khuu A; Heng DY; Haas T; Soulières D
Br J Cancer; 2012 Sep; 107(7):1059-68. PubMed ID: 22935581
[TBL] [Abstract][Full Text] [Related]
14. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
Takyar S; Diaz J; Sehgal M; Sapunar F; Pandha H
Anticancer Drugs; 2016 Jun; 27(5):383-97. PubMed ID: 26886011
[TBL] [Abstract][Full Text] [Related]
15. Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.
Foster NR; Renfro LA; Schild SE; Redman MW; Wang XF; Dahlberg SE; Ding K; Bradbury PA; Ramalingam SS; Gandara DR; Shibata T; Saijo N; Vokes EE; Adjei AA; Mandrekar SJ
J Thorac Oncol; 2015 Jul; 10(7):1099-106. PubMed ID: 26134227
[TBL] [Abstract][Full Text] [Related]
16. Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer.
Zhao S; Zhang Z; Zhang Y; Hong S; Zhou T; Yang Y; Fang W; Zhao H; Zhang L
Int J Cancer; 2019 Jun; 144(11):2854-2866. PubMed ID: 30430561
[TBL] [Abstract][Full Text] [Related]
17. A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy.
Kim SH; Kim S; Joo J; Seo HK; Joung JY; Lee KH; Chung J
BMC Cancer; 2016 Aug; 16():577. PubMed ID: 27484254
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of nephrectomy in metastatic renal cell carcinoma treated with systemic cytokine or targeted therapy: A 16-year retrospective analysis.
Kim SH; Jeong KC; Joung JY; Seo HK; Lee KH; Chung J
Sci Rep; 2018 Feb; 8(1):2974. PubMed ID: 29445167
[TBL] [Abstract][Full Text] [Related]
19. Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials.
Pasalic D; McGinnis GJ; Fuller CD; Grossberg AJ; Verma V; Mainwaring W; Miller AB; Lin TA; Jethanandani A; Espinoza AF; Diefenhardt M; Das P; Subbiah V; Subbiah IM; Jagsi R; Garden AS; Fokas E; Rödel C; Thomas CR; Minsky BD; Ludmir EB
Eur J Cancer; 2020 Sep; 136():176-185. PubMed ID: 32702645
[TBL] [Abstract][Full Text] [Related]
20. Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials.
Li L; Pan Z
Clin Breast Cancer; 2018 Feb; 18(1):63-70. PubMed ID: 28818493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]